Regeneron Pharmaceuticals (REGN) FCF Margin (2009 - 2026)

Regeneron Pharmaceuticals' FCF Margin history runs 18 years deep, the most recent figure standing at 23.53% for Q1 2026.

• On a quarterly basis, FCF Margin fell 341.0% year-over-year to 23.53% in Q1 2026; TTM through Mar 2026 was 27.57%, a 555.0% increase from a year earlier, with the FY2025 full-year figure at 28.45%, up 265.0% from the prior year.
• FCF Margin eased to 23.53% in Q1 2026 per REGN's latest filing, from 23.74% in the prior quarter.
• Across five years, FCF Margin topped out at 3919.8% in Q1 2022 and bottomed at 9.48% in Q2 2024.
• The 5-year median for FCF Margin is 26.94% (2025), against an average of 345.89%.
• Across the five-year window, FCF Margin jumped 389632 bps in 2022 and plunged 388219 bps in 2023, its largest moves.
• Year by year, FCF Margin stood at 1567.7% in 2022, then tumbled by 98 bps to 24.41% in 2023, then rose by 15 bps to 28.06% in 2024, then fell by 15 bps to 23.74% in 2025, then retreated by 1 bps to 23.53% in 2026.
• Per Business Quant, the three latest REGN FCF Margin figures stand at 23.53% (Q1 2026), 23.74% (Q4 2025), and 30.57% (Q3 2025).